Lexeo Finalizes Pivotal Trial Design for LX2006 in Friedreich Ataxia, Targets Accelerated FDA Approval by 1H 2028

summarizeSummary

Lexeo Therapeutics has finalized the pivotal trial design for its LX2006 gene therapy, targeting accelerated FDA approval for Friedreich ataxia cardiomyopathy by the first half of 2028.

check_boxKey Events

• Pivotal Trial Design Finalized

  Lexeo Therapeutics has finalized the SUNRISE-FA 2 pivotal trial protocol and statistical analysis plan for LX2006 in Friedreich ataxia cardiomyopathy.

• Accelerated Approval Pathway

  The trial design is intended to support a Biologics License Application (BLA) to the U.S. FDA under the accelerated approval pathway.

• Clear Development Timeline

  The company expects topline data in 2H 2027 and a potential BLA submission in 1H 2028, with trial initiation on track for Q2 2026.

• FDA Alignment and De-risking

  FDA feedback included removing a co-primary endpoint and approving the optimized manufacturing process, streamlining the path to approval and de-risking the program.

auto_awesomeAnalysis

Lexeo Therapeutics has announced the finalization of the pivotal SUNRISE-FA 2 trial protocol for LX2006, a gene therapy for Friedreich ataxia cardiomyopathy. This is a critical de-risking event, as the design is aligned with FDA requirements for an accelerated approval pathway. The clarity on the primary endpoint (LVMI), the approval of the manufacturing process, and the defined timeline for topline data (2H 2027) and BLA submission (1H 2028) provide a clear path to market for a key pipeline asset. This significantly boosts investor confidence in the program's future.